Previous 10 | Next 10 |
Blueprint Medicines press release (NASDAQ:BPMC): Q4 GAAP EPS of -$5.40 misses by $4.25. Revenue of $107M (+213.7% Y/Y) beats by $2.86M. Blueprint Medicines today announced it anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AY...
Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results -- Achieved $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues in 2021 -- -- Anticipate approximately $115 million to $130 million in AYVAKIT net product revenues and $180 m...
Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is -$1.57 and the consensus revenue estimate is $104.14M (+205.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of the time...
Blueprint Medicines to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 16, 2022 PR Newswire CAMBRIDGE, Mass. , Feb. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a l...
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis -- Positive opinion based on results from two clinical trials that comprise the largest clinical trial dataset in advanced systemic mas...
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team -- Philina Lee, Ph.D., promoted to Chief Commercial Officer -- -- Helen Ho, Ph.D., role expanded to Chief Business Officer - -- Demonstrates strong bench of talent and commitment to diversity in role...
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership -- Achieved full-year 2021 preliminary global net product revenue for AYVAKIT of approximately $52.9 million, representing an increase of approximately 150% over 2020 based on stron...
Blueprint Medicines Announces CEO and Leadership Transition Plan -- Jeff Albers to transition to role of Executive Chairman of the Board of Directors -- -- Chief Operating Officer Kate Haviland appointed President and Chief Executive Officer -- -- Chief Commercial Office...
Blueprint Medicines Completes Acquisition of Lengo Therapeutics - Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations - Investigational New Drug application for LNG-45...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...